(Q33183184)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11747939%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

review article

1 reference

title

Oxazolidinone antibiotics (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11747939%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11747939%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

2

R N Jones

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11747939%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

language of work or name

English

0 references

publication date

1 December 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11747939%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11747939%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

volume

358

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11747939%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

issue

9297

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11747939%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

page(s)

1975-1982

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11747939%20AND%20SRC:MED&resulttype=core&format=json

Emergence of vancomycin resistance in coagulase-negative staphylococci

5 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Bacteremia due to viridans streptococci in neutropenic patients: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

In vitro activity and spectrum of LY333328, a novel glycopeptide derivative.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Daptomycin disrupts membrane potential in growing Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Oxazolidinones: new antibacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Oxazolidinones: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

A novel antimicrobial agent joins the battle against resistant bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Ribosomes from an oxazolidinone-resistant mutant confer resistance to eperezolid in a Staphylococcus aureus cell-free transcription-translation assay

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Susceptibility testing with linezolid by different methods, in relation to published 'general breakpoints'.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Comparative in vitro and bactericidal activity of oxazolidinone antibiotics against multidrug-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

In vitro activities in new oxazolidinone antimicrobial agents against enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Linezolid breakpoints

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

MICs of oxazolidinones for Rhodococcus equi strains isolated from humans and animals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

In vitro activities of linezolid against multiple Nocardia species

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibil

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to the novel oxazolidinones eperezolid (PNU-100592) and linezolid (PNU-100766)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

In vitro antibiotic synergy against Flavobacterium meningosepticum: implications for therapeutic options

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

In vitro activities of linezolid alone and in combination with amoxicillin, clarithromycin, and metronidazole against Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

In vitro activity of linezolid and eperezolid, two novel oxazolidinone antimicrobial agents, against anaerobic bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

In vitro activity of linezolid and eperezolid against anaerobic bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Oxazolidinones, a new class of synthetic antituberculosis agent in vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

In-vitro activity of oxazolidinones against Mycobacterium avium complex

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Activities of linezolid against rapidly growing mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Linezolid resistance in a clinical isolate of Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Efficacy of linezolid in experimental otitis media

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Efficacy of linezolid in a staphylococcal endocarditis rabbit model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Emerging therapies for serious gram-positive bacterial infections: a focus on linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Methicillin-resistant Staphylococcus aureus infection in a renal allograft recipient treated successfully with a novel new antimicrobial agent (linezolid): new treatment options for infections due to resistant organisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Successful treatment of vertebral osteomyelitis with linezolid in a patient receiving hemodialysis and with persistent methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus bacteremias.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinupristin/dalfopristin).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Successful treatment of disseminated Mycobacterium chelonae infection with linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

New approaches to reduce Staphylococcus aureus nosocomial infection rates: treating S. aureus nasal carriage

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Linezolid Pediatric Pneumonia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906964-1

7 January 2021

10.1016/S0140-6736(01)06964-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11747939%20AND%20SRC:MED&resulttype=core&format=json

release_inqg6xlqevcdzdredho45atadm

5 December 2019

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/inqg6xlqevcdzdredho45atadm

24 November 2022

mapped directly with Wikidata item

1 reference